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Abstract
Background: The World Health Organization (WHO) recommends viral load (VL) measurement as the preferred
monitoring strategy for HIV-infected individuals on antiretroviral therapy (ART) in resource-limited settings. The
new WHO guidelines 2016 continue to define virologic failure as two consecutive VL ≥1000 copies/mL (at least 3 months
apart) despite good adherence, triggering switch to second-line therapy. However, the threshold of 1000 copies/mL for
defining virologic failure is based on low-quality evidence. Observational studies have shown that individuals with low-
level viremia (measurable but below 1000 copies/mL) are at increased risk for accumulation of resistance mutations and
subsequent virologic failure. The SESOTHO trial assesses a lower threshold for switch to second-line ART in patients with
sustained unsuppressed VL.
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Methods: In this multicenter, parallel-group, open-label, randomized controlled trial conducted in Lesotho, patients on
first-line ART with two consecutive unsuppressed VL measurements ≥100 copies/mL, where the second VL is between
100 and 999 copies/mL, will either be switched to second-line ART immediately (intervention group) or not be switched
(standard of care, according to WHO guidelines). The primary endpoint is viral resuppression (VL < 50 copies/mL) 9 months
after randomization. We will enrol 80 patients, giving us 90% power to detect a difference of 35% in viral resuppression
between the groups (assuming two-sided 5% alpha error). For our primary analysis, we will use a modified
intention-to-treat set, with those lost to care, death, or crossed over considered failure to resuppress, and using logistic
regression models adjusted for the prespecified stratification variables.
Discussion: The SESOTHO trial challenges the current WHO guidelines, assessing an alternative, lower VL threshold for
patients with unsuppressed VL on first-line ART. This trial will provide data to inform future WHO guidelines on VL
thresholds to recommend switch to second-line ART.
Trial registration: ClinicalTrials.gov (NCT03088241), registered May 05, 2017
Keywords: HIV, Viral suppression, Treatment failure, First-line antiretroviral therapy failure, Switch to second-line antiretroviral
therapy, Lesotho, Southern Africa, Randomized controlled trial, Low-level viremia
Background
The management of first-line antiretroviral therapy
(ART) failure is a crucial step to achieve the third pillar
of the UNAIDS 90–90-90 targets, namely viral suppres-
sion in 90% of all HIV-positive individuals on treatment,
and ensure successful treatment outcomes [1]. The World
Health Organization (WHO) recommends viral load (VL)
measurement as the preferred monitoring strategy for
HIV-infected individuals on ART in resource-limited set-
tings [2, 3]. The current WHO and Lesotho guidelines de-
fine virologic failure as two subsequent VL ≥1000 copies/
mL despite good adherence [2–4]. Specifically, the guide-
lines recommend that in case of a VL ≥1000 copies/mL,
the patient should undergo enhanced adherence counsel-
ing, and a second VL test should be performed 8–12 weeks
later. A second VL ≥1000 copies/mL despite good adher-
ence triggers switch to an appropriate second-line regi-
men, whereas if VL returns to < 1000 copies/mL, first-line
ART is continued unaltered. Thus, the WHO guidelines
define patients with a VL below 1000 copies/mL as “non-
failures”. However, the guidelines acknowledge that the
threshold of 1000 copies/mL is based on low-quality evi-
dence and, in fact, the optimal threshold for defining viro-
logic failure and for switching ART regimens has not been
established. In contrast, European [5] and North American
[6] guidelines suggest to switch at much lower thresholds,
namely above 50 and 200 copies/mL, respectively.
Several observational cohort studies and systematic re-
views from resource-rich and resource-limited settings
have demonstrated the emergence of major drug resist-
ant mutations (DRMs) and a high risk of virologic failure
among patients with sustained low-level viremia [7–16].
A recently published study from our research consor-
tium in Lesotho supports these findings, showing that
94% (17/18) of patients with VL between 80 and 999
copies/mL harbored critical DRM against at least two
drugs of the current first-line regimen. In this small pa-
tient subgroup with VL between 80 and 999 copies/mL,
who were continued on first-line ART as per national
guidelines, none achieved viral resuppression one year
later [17, 18].
In high-income settings with easy access to VL moni-
toring, individualized patient management and a “watch-
and-wait” strategy with monthly monitoring for patients
with low-level viremia may be appropriate [5, 6]. How-
ever, if patients in resource-limited settings with a VL
below 1000 copies/mL are defined as “non-failures”, they
will not receive any follow-up VL for at least 6 to
12 months – depending on the frequency of VL moni-
toring recommended in national guidelines and on the
availability of VL in a given setting – and may thus con-
tinue a failing regimen for considerable time. While the
risk of onward HIV transmission and disease progres-
sion seems to be low in patients with low-level viremia
[19–21], defining patients with VLs below 1000 copies/
mL as “non-failures” in resource-limited settings, such
as Lesotho, may bear a considerable risk from an indi-
vidual as well as public health perspective as progression
to full failure with high viremia will remain undetected
for months.
To our knowledge there are no published or ongoing
randomized controlled trials (RCTs) from resource-
limited settings assessing VL thresholds for switch to
second-line ART, as summarized in the recent viewpoint
of Ellman et al. in the Journal of the International AIDS
Society [22]. This manuscript is the study protocol of
the SESOTHO (“Switch Either near Suppression Or
THOusand”) trial. The SESOTHO trial challenges the
current WHO guidelines, assessing whether a threshold
of 100 copies/mL compared to the WHO-defined threshold
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of 1000 copies/mL for switching to second-line ARTamong
HIV-positive patients on first-line ART will lead to higher
viral resuppression rates.
Methods
Setting and design
The SESOTHO trial will be conducted in the district of
Butha-Buthe, in northern Lesotho, Southern Africa.
Lesotho has an estimated adult HIV prevalence of 25%
[23]. Little is currently known regarding the third
UNAIDS target (viral suppression in 90% of people on
ART) in Lesotho as routine VL monitoring has been in-
troduced only recently. Butha-Buthe is a rural district
with an estimated 110,000 habitants, who are mostly
subsistence farmers or mine workers, or construction or
domestic workers in neighboring South Africa. According
to the Demographic Health Survey 2014, the adult HIV
prevalence in the district is 21.2% [23].
Since the beginning of 2016 the district hospital of
Butha-Buthe offers VL testing, thanks to a close collab-
oration between the Ministry of Health of Lesotho, the
Swiss Tropical and Public Health Institute (Swiss TPH),
Department of Biomedicine University of Basel and Soli-
darMed, Swiss Organization for Health in Africa. All pa-
tients on ART in Butha-Buthe district have access to
routine VL monitoring and VL results are stored in an
encrypted and password-protected online database
(https://visibleimpact.org/projects/1261-molecular-hiv-mo
nitoring-in-lesotho).
This is a multicenter (2 hospitals [Butha-Buthe
Government Hospital and Seboche St Charles Mission
Hospital] and 10 rural health centers), parallel-group
(1:1 allocation), open-label, superiority, prospective RCT
in a resource-limited setting.
Screening, randomization and interventions
Patients will be screened for eligibility according to the
criteria in Table 1 by the study physician using the above
mentioned online database with all VL results from the
participating health facilities in Butha-Buthe district.
Figure 1 displays the flow chart with the screening and
randomization process.
Eligible patients will be invited to join the study, and
informed consent will be sought from the patient by the
study physician and a study nurse who speaks the local
language. Eligible and consenting patients will be ran-
domized by the study physician in a 1:1 allocation, using
sealed, opaque, and sequentially-numbered envelopes,
stratified by centres (hospitals; health centres), demo-
graphic group (adults; children <16y; pregnant women)
and level of VL at enrolment (100–599; 600–999 copies/
mL) with randomly-varying block sizes. The randomization
list was generated by the trial statistician and the envelopes
were prepared by persons independent from the trial.
According to their randomized allocation, participants will
either be immediately switched to a second-line ART regi-
men (intervention group) or remain on first-line ART (con-
trol group, standard of care). Choice of second-line ART is
based on the national ART guidelines [4].
Primary endpoint
The primary endpoint is viral resuppression (VL < 50
copies/mL) 9 months after randomization. The rationale
for this time-point is that, according to national guide-
lines, VL should be measured 6 months after switch to
second-line ART. If this VL is above 1000 copies/mL,
enhanced adherence counseling is introduced and a
follow-up VL is performed 3 months later [4]. Hence,
9 months is the earliest possible time point for virologic
failure (versus viral resuppression) after switch to
second-line ART. Moreover, using 9 months instead of
6 months takes into account that PI-based regimens
might need more time to achieve viral resuppression.
Secondary, exploratory, and subgroup endpoints
These endpoints are outlined in Table 2. We defined one
pre-specified subgroup: Individuals showing a > 0.5 drop
in log10 VL from the first screening VL measurement
(before enhanced adherence counseling) to the second
screening VL measurement (i.e. VL at enrolment). Ac-
cording to WHO guidelines [2], these individuals would
not be switched to second-line ART regardless of their
absolute VL level. However, such patients are considered
eligible for inclusion in this trial, and hence they could
be randomized to either treatment arm. The rational for
Table 1 Eligibility criteria for the SESOTHO trial
Inclusion Criteria Exclusion Criteria
a) On non-nucleoside reverse transcriptase inhibitor (NNRTI)
based ART (standard first-line regimen in Lesotho) for at
least 6 months
b) Two consecutive VL ≥100 copies/mL, with the latest VL
between 100 and 999 copies/mL
c) Participant lives and/or works in the district of Butha-Buthe
and declares to seek follow-up at one of the study-facilities
d) Signed written informed consent. For children aged < 18 years
and illiterate patients, a literate caregiver or witness, respectively,
must provide written informed consent (see Ethical considerations).
a) On ART less than 6 months
b) On protease inhibitor (PI) or integrase inhibitor containing ART regimen
c) Poor adherence (self-reported at least 1 dose of a once-daily regimen
missed in the last 4 weeks, respectively two doses of a twice-daily-regimen)
d) Clinical WHO stage 3 or 4 at enrolment
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this decision is based on results of our previous study
[17]. In that study, all patients with a > 0.5 drop in log10
VL and a second VL between 100 and 999 copies/mL
harboured HIV with relevant drug resistance mutations,
indicating a need for switch to second-line ART despite
the large drop in VL after enhanced adherence counsel-
ing. We assume that individuals showing a > 0.5 drop in
log10 VL but still with VL ≥100 copies/mL will benefit
from switching to second-line ART. Therefore, we
hypothesize the same outcome (significant difference in
viral resuppression between the two treatment arms) in
this subgroup.
Data collection and management, biologic material, and
follow-up
All data collected during the scheduled visits will be
recorded on paper case report forms and subse-
quently entered into a password-protected database
using EpiData (v4.0.2.101). Access and type of activ-
ity for an individual is regulated by privileges
assigned to his/her user identification code and pass-
word. Data will be double-entered, and modifications
are retrievable for reviewing. Apart from the in-
formed consent form, all study documents will not
contain any names but solely the study-ID. There is
one master list with the subject identification code,
which will be stored in a password-protected,
encrypted online cloud and only accessible for pre-
defined study personnel. Participant files will be
maintained in storage for a period of at least 10 years
after completion of the study.
Participants will undergo phlebotomy at recruit-
ment, 3, 6, 9, and 24 months after randomization.
For each participant, study-ID-coded blood samples
will be stored at − 80 °C at the laboratory of Butha-
Buthe hospital. All samples collected fall under the
biobank agreement, accepted by the EKNZ (EKNZ
BASEC UBE-Req. 2016–00708) and the ethics com-
mittee in Lesotho (ID134–2016). VL determination
will be done on COBAS TaqMan® HIV-1 Test, v2.0
(Roche Diagnostics) with reliable lower limit of de-
tection of 20 copies/mL following the manufacturer’s
protocol for VL analysis. Figure 2 displays the
SPIRIT flow diagram with the overview of data col-
lection, laboratory assessments and follow-up visits.
In both groups, follow-up is in-line with Lesotho
guidelines [4] with additional laboratory testing at 3
and 9 months.
Fig. 1 Flow Chart of the SESOTHO trial: screening, randomization and primary endpoint. The first part of the flow chart (incl. EAC and follow-up
VL) represents routine ART monitoring in the study district. a 10–14 weeks after the time point the patient has been informed. b stratified by centres,
demographic groups and VL level at enrolment
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Sample-size
Studies assessing virologic outcomes in patients with a
VL < 1000 copies/mL in resource-limited settings are
scarce. Most studies found viral resuppression rates after
switch to second-line of 60–80% (with various defini-
tions of viral resuppression levels and time points)
[24–28]. Due to the limited published data, our sam-
ple size assumptions were primarily based on our
own data from a previous cohort study in Lesotho, al-
though the sample size of that study was small and
therefore the confidence intervals of our estimates
were wide [17]. Based on those data, we expect 9-
month viral resuppression rates of 25% in the control
arm and 60% in the intervention arm, assuming a
lost-to-follow-up (LTFU) rate of 10% in each arm,
and counting participants who are LTFU as failures,
Table 2 Secondary, exploratory and subgroup endpoints of the SESOTHO trial
Definition Time point following
randomization
Remarks
Secondary endpoints
VL level Proportion of participants with different levels
(VL < 100, < 200, < 400, < 1000 copies/mL)
9 months
VL at 6 months Proportion of participants with viral
resuppression (< 50 copies/mL)
6 months
Sustained virologic failure Proportion of participants with unsuppressed
VL > 50 copies/mL at 6 and 9 months
6 and 9 months
Adherence Proportion of participants with good adherence 3, 6, and 9 months Definition of “good adherence”:
self-reported no dose missed of
a once-daily-regimen, respectively
less than two doses of a twice-daily-
regimen, during the last month
Clinical outcomes Change in values (versus values at baseline)
of body-weight (kg), CD4-cell count (cells/μL),
haemoglobin (g/dL), lipids (total cholesterol,
LDL, HDL, triglycerides; mmol/L); proportion
of patients with newly-recorded clinical
WHO-stage 3 or 4 events; proportion of
patients died (all-causes)
9 months
(Serious) Adverse Events Proportion of patients with Adverse Events
(AE) or Serious Adverse Events (SAE)
9 months AE and SAE are graded according
to Common Terminology Criteria
for Adverse Events (v4.0, published
May 28, 2009)
Long-term follow-up Proportion of patients that are alive, retained
in care and virologically suppressed
24 months Definition of “virologically suppressed”:
< 50 copies/mL
Potential effect modifiers
Primary endpoint by
demographic groups
Viral resuppression by adults vs children vs
pregnant women
9 months Definition of “viral resuppression”:
< 50 copies/mL
Primary endpoint by
baseline VL groups
Viral resuppression by baseline VL 100–599 vs
600–999 copies/mL
9 months Definition of “viral resuppression”:
< 50 copies/mL
Exploratory endpoints
Cost-effectiveness Staff costs (clinical and laboratory); costs of ARVs;
costs of drugs for prevention of opportunistic
infections and other concomitant medications;
laboratory costs (CD4 cell count, VL, blood
chemistry, blood count and other diagnostic
procedures); estimation of health impact/benefits
outcomes (e.g. DALY)
Between baseline and
9 months and 24 months
(long-term follow-up)
Drug resistance mutations Prevalence of major drug resistance mutations a)
on all baseline VLs and b) on all VLs that remain
unsuppressed (> 50 copies/mL) at 9 months for
all samples for which an RT-PCR amplification
is successful
At baseline and at 9 months Definition of “major drug resistance
mutations”: Stanford University HIV
Resistance Database
(http://hivdb.stanford.edu)
Subgroup endpoint
Log-drop Viral resuppression among individuals with a > 0.5
drop in log10 VL between the first screening VL
and the second screening VL (i.e. VL at enrolment)
9 months Definition of “viral resuppression”:
< 50 copies/mL
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i.e. not virologically resuppressed. Assuming a two-
sided type 1 error of 5%, 80 individuals (40 per
group) are needed to detect a 35% difference with
90% power. This sample size provides 78% power to
detect a 30% difference. With an estimated 10% trial
participation refusal rate, we need to screen approxi-
mately 90 participants.
Analyses
Analyses will be performed following CONSORT guide-
lines [29] and a modified intention-to-treat principle in-
cluding all participants as randomized, but LTFU, death
(all-causes), and change in regimen line prior to deter-
mination of the primary endpoint considered as failures.
Change in regimen line is defined as a change to a new
drug class (i.e. from a NNRTI to a PI). Substitutions
within same drug class (i.e. changing from tenofovir to
zidovudine because of renal impairment) will not be
considered as a “change in regimen line”. We will per-
form a sensitivity analysis (per protocol set) including
only participants who finished the 9 months according
to the protocol (that is, alive, retained in care, no change
in regimen line other than that indicated by the
randomization, and VL measurement available at
9 months). We will present a CONSORT flow chart of
the participants, including screening, enrollment and
follow-up. Baseline characteristics will be presented by
randomized groups using appropriate summary statis-
tics; no formal testing will be performed [30]. Outcomes
will be summarised at all follow-up visits by randomized
groups using appropriate summary statistics. Analysis of
the primary endpoint will use a logistic regression model
adjusted for the randomisation stratification factors
(centers, demographic groups, and VL at enrolment, as
detailed above). For analyses of other binary outcomes
and continuous outcomes we will use similar logistic
and linear regression models, respectively. Potential ef-
fect modifiers (as shown in Table 2) will be assessed by
incorporating the appropriate interections into the re-
gression models.
All analyses will be performed using R (the R Founda-
tion for Statistical Computing) or Stata (version 14, Stata
Corporation, Austin/Texas, USA). For all tests, we will
use two-sided p-values with alpha 0.05 level of signifi-
cance. A separate detailed data analysis plan will be de-
veloped, including for the cost-effectiveness analysis.
Monitoring, auditing, and data safety and monitoring
board (DSMB)
A minimum of two external monitoring visits will assess
adherence to the trial protocol, accuracy of completed
case report forms, and the electronic dataset. The
Pharmaceutical Medicine Unit of the Division Medicines
Research (MedRes) at the Swiss Tropical and Public
Health Institute, which acts as an independent academic
contract research organization, will perform the moni-
toring. The Principal Investigator agrees to allow inspec-
tors from regulatory agencies to review records and will
assist the inspectors in their duties, if requested.
Given that the recruitment is projected to happen
fairly quickly, determination of the primary endpoint is
after 9 months, safety profiles of all drugs are well-
known, and the intervention does not include any new
drugs, a DSMB will not be installed.
Ethical considerations
This trial has been approved by the National Health
Research and Ethics Committee of the Ministry of
Health of Lesotho (ID48–2017, 05.07.2017) and the
Ethics committee in Switzerland (Ethikkomission
Nordwest- und Zentralschweiz; EKNZ BASEC UBE
2017–00201, 10.04.2017).
Fig. 2 SPIRIT Flow Diagram of the SESOTHO trial
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Prior to randomization, all participants will provide
oral and written informed consent: The study nurse/
physician will explain the information sheet to partici-
pants. Once all open questions have been clarified and
upon agreement to participate, the participant will sign
the informed consent form. Iliterate participants will
provide a thumb-print and a witness (independent to
the trial and > 21 years old), chosen by the participant,
will co-sign the form. For children and young adults
aged < 18 years, a literate caregiver > 21 years old (per-
son that takes care of the child/young adult) will provide
oral and written informed consent. The informed con-
sent is provided in English and the local language,
Sesotho, and the participant will receive a copy of the
consent form in written format to take away. The par-
ticipant has the right to withdraw at any time without
giving reasons. In case of withdrawal, only data collected
until the time of withdrawal will be used for research
purposes (fully anonymized, identifyer removed). A sep-
arate, detailed safety monitoring plan has been devel-
oped to handle (S)Aes, in-line with swiss and lesotho
ethics regulations. The study physician is responsible for
all safety procedures. If a participant develops an adverse
event of Grade 2 or higher at last study visit, he/she will
remain under observation by the study physician even
after study termination, until the adverse event is re-
solved or stabilized.
Participation in this study is not anticipated to cause
any substantial additional risk or cost to the participant.
Therefore we will not pay compensation to the partici-
pants. Free AirTime (local prepaid money for cellphone
usage) will be provided to the study nurses/physicians
for the duties of the study. We will consider a step-wise
remuneration for study nurses/physicians per enrolled
study participant.
Trial status and recruitment
The trial has been launched at the two study sites with
the highest patient load (Butha-Buthe Hospital and
Seboche St Charles Hospital) and the first patient was
recruited at Butha-Buthe Hospital on August 01, 2017. If
necessary, recruitment will subsequently be rolled out to
rural health centres. We anticipate identifying approxi-
mately 14 eligible participants/month and a 10% refusal
rate, therefore we project a total recruitment period of
7 months to achive our target sample size of 80 patients.
Discussion
By the end of 2016, an estimated 11.7 million individ-
uals, representing 60% of all people living with HIV in
Eastern and Southern Africa, were receiving ART [31].
In resource-limited settings, scaling up the number of
people on ART relied strongly on the WHO public-
health approach [32]. Standardized, clear and pragmatic
guidelines allowed decentralization of care to less spe-
cialized health care facilities, such as nurse-led health
centers [33]. This means that HIV care in such settings
is often provided by less-specialized health personnel
and so management usually strictly follows national
ART guidelines, which in turn follow WHO guidelines.
The 2013 WHO guidelines introduced VL monitoring as
the preferred monitoring strategy for individuals on
ART, even in resource-limited settings. Although imple-
mentation of VL monitoring is challenging, i.e. in
laboratory infrastructure, technical capacities and afford-
ability, data from 12 countries in Eastern and Southern
Africa showed that about 44% of people on ART had ac-
cess to VL monitoring and all countries but one in the
region have established a national policy on routine VL
monitoring [31]. With VL monitoring becoming avail-
able for millions of patients on ART in this region, it is
important to reassess the WHO recommendations on
virologic failure. Initially, WHO guidelines defined viro-
logic failure with a threshold of 5000 copies/mL [34].
This threshold was lowered to 1000 copies/mL in the
2013 revised WHO guidelines and was maintained in re-
cent consolidations in 2016 and 2017 [35]. However, the
WHO guidelines and the Lesotho guidelines acknow-
ledge that there is no clear evidence for supporting a
threshold of 1000 copies/mL [2, 4]. In resource-limited
settings, where care strictly follows national and WHO
guidelines, the decision to define patients with sustained
unsuppressed VL below 1000 copies as “non-failures”,
and therefore continue with unaltered drug regimen,
bears the danger that emerging virologic failures will re-
main unrecognized over unnecessarily long periods des-
pite the availability of VL monitoring.
This trial has several limitations: The proposed switch
to second-line at a lower threshold will lead to a higher
number of people receiving second-line ART, which re-
mains 2–3 times more expensive than first-line ART
[36]. Moreover, current first-line therapy in Southern
Africa usually consists of tenofovir disoproxil fumarate,
lamivudine, and efavirenz, available as one pill once daily
[37]. In contrast, second-line ART typically consists of
ritonavir-boosted lopinavir, lamivudine, and zidovudine,
a regimen consisting of two to three pills twice daily. A
higher pill burden has been shown to reduce adherence
[38]. While the current WHO threshold may be associ-
ated with switching too late, the threshold in the inter-
vention group of the SESOTHO trial may, for some
individuals, lead to unnecessary (or premature) switches,
with higher cost to the health system and higher pill
burden to the patient. To address these limitations we
plan a) a cost-effectiveness analysis, and b) genotypic
resistance testing on baseline samples, in order to de-
termine how many patients were switched without
detectable drug resistance mutations in both groups.
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In summary, the SESOTHO trial aims to generate evi-
dence to inform future WHO guidelines, regarding
whether a lower VL threshold (e.g. at 100 copies/mL) for
switching to second-line ART in resource-limited set-
tings will result in higher rates of viral resuppression. To
our knowledge this is the first and only ongoing RCT
addressing the question of VL threshold for switch to
second-line ART in Southern Africa.
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